Krystal Biotech, Inc. Operating Expenses
Krystal Biotech, Inc. (KRYS) reported Operating Expenses of $60.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-03
- Krystal Biotech, Inc. operating expenses for the quarter ending 2026-06-30 was $60.80M, a 7.35% increase year-over-year.
- Krystal Biotech, Inc. operating expenses for the quarter ending 2026-03-31 was $62.67M, a 20.68% increase year-over-year.
- Krystal Biotech, Inc. operating expenses for the quarter ending 2025-12-31 was $62.84M, a 26.27% increase year-over-year.
- Krystal Biotech, Inc. operating expenses for the quarter ending 2025-09-30 was $56.43M, a 8.05% decline year-over-year.
- Krystal Biotech, Inc. operating expenses for fiscal 2025 was $227.84M, a 1.36% increase from fiscal 2024.
- Krystal Biotech, Inc. operating expenses for fiscal 2024 was $224.77M, a 40.20% increase from fiscal 2023.
- Krystal Biotech, Inc. operating expenses for fiscal 2023 was $160.32M, a 10.41% increase from fiscal 2022.
- Krystal Biotech, Inc. operating expenses for fiscal 2022 was $145.20M, a 112.66% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $60.80M 10-Q · filed 2026-08-03 | $123.47M 10-Q · filed 2026-08-03 | $186.31M derived: sum of 3 quarters · filed 2026-08-03 | $242.73M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $62.67M 10-Q · filed 2026-05-04 | $125.50M derived: sum of 2 quarters · filed 2026-05-04 | $181.93M derived: sum of 3 quarters · filed 2026-05-04 | $238.57M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $62.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $119.26M derived: sum of 2 quarters · filed 2026-02-17 | $175.90M derived: sum of 3 quarters · filed 2026-08-03 | $227.84M 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $56.43M 10-Q · filed 2025-11-03 | $113.07M derived: sum of 2 quarters · filed 2026-08-03 | $165.00M 10-Q · filed 2025-11-03 | $214.76M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $56.64M 10-Q · filed 2026-08-03 | $56.73M 10-Q · filed 2025-08-04 | $108.57M 10-Q · filed 2026-08-03 | $108.74M 10-Q · filed 2025-08-04 | $158.34M derived: sum of 3 quarters · filed 2026-08-03 | $219.71M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $51.93M 10-Q · filed 2026-05-04 | $52.01M 10-Q · filed 2025-05-06 | $101.69M derived: sum of 2 quarters · filed 2026-05-04 | $163.06M derived: sum of 3 quarters · filed 2026-05-04 | $224.78M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $49.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $111.13M derived: sum of 2 quarters · filed 2026-02-17 | $172.85M derived: sum of 3 quarters · filed 2026-02-17 | $224.77M 10-K · filed 2026-02-17 | $224.82M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $61.37M 10-Q · filed 2025-11-03 | $61.41M 10-Q · filed 2024-11-04 | $123.09M derived: sum of 2 quarters · filed 2025-11-03 | $175.00M 10-Q · filed 2025-11-03 | $175.06M 10-Q · filed 2024-11-04 | $213.92M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2024-06-30 | $61.72M 10-Q · filed 2025-08-04 | $113.65M 10-Q · filed 2025-08-04 | $152.55M derived: sum of 3 quarters · filed 2026-02-17 | $187.10M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2024-03-31 | $51.93M 10-Q · filed 2025-05-06 | $90.83M derived: sum of 2 quarters · filed 2026-02-17 | $125.38M derived: sum of 3 quarters · filed 2026-02-17 | $163.43M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2023-12-31 | $38.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $73.44M derived: sum of 2 quarters · filed 2026-02-17 | $111.49M derived: sum of 3 quarters · filed 2026-02-17 | $160.32M 10-K · filed 2026-02-17 | $160.43M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | $34.55M 10-Q · filed 2024-11-04 | $72.60M derived: sum of 2 quarters · filed 2024-11-04 | $121.42M 10-Q · filed 2024-11-04 | $156.19M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $38.05M 10-Q · filed 2024-08-05 | $86.87M 10-Q · filed 2024-08-05 | $121.64M derived: sum of 3 quarters · filed 2025-02-19 | $153.09M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $48.82M 10-Q · filed 2024-05-06 | $83.59M derived: sum of 2 quarters · filed 2025-02-19 | $115.05M derived: sum of 3 quarters · filed 2025-02-19 | $143.80M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $34.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $66.22M derived: sum of 2 quarters · filed 2025-02-19 | $94.97M derived: sum of 3 quarters · filed 2025-02-19 | $145.20M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $31.45M 10-Q · filed 2023-11-06 | $60.20M derived: sum of 2 quarters · filed 2023-11-06 | $110.42M 10-Q · filed 2023-11-06 | $132.30M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $28.75M 10-Q · filed 2023-08-07 | $78.97M 10-Q · filed 2023-08-07 | $100.85M derived: sum of 3 quarters · filed 2024-02-26 | $116.50M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $50.22M 10-Q · filed 2023-05-08 | $72.10M derived: sum of 2 quarters · filed 2024-02-26 | $87.75M derived: sum of 3 quarters · filed 2024-02-26 | $104.14M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $21.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $37.53M derived: sum of 2 quarters · filed 2024-02-26 | $53.92M derived: sum of 3 quarters · filed 2024-02-26 | $68.28M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $15.65M 10-Q · filed 2022-11-07 | $32.05M derived: sum of 2 quarters · filed 2022-11-07 | $46.40M 10-Q · filed 2022-11-07 | $56.82M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $16.39M 10-Q · filed 2022-08-08 | $30.75M 10-Q · filed 2022-08-08 | $41.17M derived: sum of 3 quarters · filed 2023-02-27 | $50.85M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $14.35M 10-Q · filed 2022-05-09 | $24.77M derived: sum of 2 quarters · filed 2023-02-27 | $34.45M derived: sum of 3 quarters · filed 2023-02-27 | $41.41M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $10.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $20.10M derived: sum of 2 quarters · filed 2023-02-27 | $27.05M derived: sum of 3 quarters · filed 2023-02-27 | $33.00M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $9.68M 10-Q · filed 2021-11-08 | $16.63M derived: sum of 2 quarters · filed 2021-11-08 | $22.58M 10-Q · filed 2021-11-08 | $28.73M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2020-06-30 | $6.95M 10-Q · filed 2021-08-09 | $12.90M 10-Q · filed 2021-08-09 | $19.05M derived: sum of 3 quarters · filed 2021-08-09 | $24.40M derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2020-03-31 | $5.95M 10-Q · filed 2021-05-10 | $12.10M derived: sum of 2 quarters · filed 2021-05-10 | $17.44M derived: sum of 3 quarters · filed 2021-05-10 | $23.33M derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $11.50M derived: sum of 2 quarters · filed 2021-03-01 | $17.39M derived: sum of 3 quarters · filed 2021-03-01 | $22.08M 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $5.34M 10-Q · filed 2020-11-09 | $11.23M derived: sum of 2 quarters · filed 2020-11-09 | $15.93M 10-Q · filed 2020-11-09 | $20.14M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $5.89M 10-Q · filed 2020-08-07 | $10.59M 10-Q · filed 2020-08-07 | $14.80M derived: sum of 3 quarters · filed 2020-08-07 | $17.77M derived: sum of 4 quarters · filed 2020-08-07 | ||||
| 2019-03-31 | $4.69M 10-Q · filed 2020-05-04 | $8.91M derived: sum of 2 quarters · filed 2020-05-04 | $11.88M derived: sum of 3 quarters · filed 2020-05-04 | $14.33M derived: sum of 4 quarters · filed 2020-05-04 | ||||
| 2018-12-31 | $4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $7.19M derived: sum of 2 quarters · filed 2020-03-10 | $9.64M derived: sum of 3 quarters · filed 2020-03-10 | $11.92M 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | $2.97M 10-Q · filed 2019-11-04 | $5.42M derived: sum of 2 quarters · filed 2019-11-04 | $7.70M 10-Q · filed 2019-11-04 | $9.20M derived: sum of 4 quarters · filed 2019-11-04 | ||||
| 2018-06-30 | $2.45M 10-Q · filed 2019-08-05 | $4.73M 10-Q · filed 2019-08-05 | $6.22M derived: sum of 3 quarters · filed 2019-08-05 | $8.32M derived: sum of 4 quarters · filed 2019-08-05 | ||||
| 2018-03-31 | $2.28M 10-Q · filed 2019-05-07 | $3.77M derived: sum of 2 quarters · filed 2019-05-07 | $5.87M derived: sum of 3 quarters · filed 2019-05-07 | $6.58M derived: sum of 4 quarters · filed 2019-05-07 | ||||
| 2017-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $3.59M derived: sum of 2 quarters · filed 2018-11-05 | $4.31M derived: sum of 3 quarters · filed 2018-11-05 | $4.77M 10-K · filed 2018-03-12 | ||||
| 2017-09-30 | $2.09M 10-Q · filed 2018-11-05 | $2.81M derived: sum of 2 quarters · filed 2018-11-05 | $3.27M 10-Q · filed 2018-11-05 | $3.89M derived: sum of 4 quarters · filed 2018-11-05 | ||||
| 2017-06-30 | $715.00K 10-Q · filed 2018-08-06 | $1.18M 10-Q · filed 2018-08-06 | $1.80M derived: sum of 3 quarters · filed 2018-08-06 | $2.12M derived: sum of 4 quarters · filed 2018-08-06 | ||||
| 2017-03-31 | $465.00K 10-Q · filed 2018-05-07 | $1.08M derived: sum of 2 quarters · filed 2018-05-07 | $1.41M derived: sum of 3 quarters · filed 2018-05-07 | |||||
| 2016-12-31 | $620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $942.00K derived: sum of 2 quarters · filed 2018-03-12 | $1.14M 10-K · filed 2018-03-12 | |||||
| 2016-09-30 | $322.00K 10-Q · filed 2017-11-13 | $523.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |